Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Delighted to see three pioneers of cellular immunotherapy Drs. Steven Rosenberg, Michel Sadelain, and Carl June named joint laureates of the 2026 Tang Prize in Biopharmaceutical Science for their groundbreaking work on TIL and CAR‑T therapies.
The Tang Prize has become a recognized precursor to the Nobel, with a track record of spotting breakthroughs early just think Allison + Honjo: Tang 2014, Nobel 2018.
A remarkable and well‑deserved moment for the field.”
Other articles featuring Vivek Subbiah on OncoDaily.